Autoinjectors Market Size To Reach $20.6 Billion By 2030

Autoinjectors Market Growth & Trends

The global autoinjectors market size is expected to reach USD 20.6 billion by 2030, registering a CAGR of 15.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising incidence of anaphylactic shock and other diseases such as diabetes, rheumatoid, & multiple sclerosis along with increasing approvals of auto-injectors are impelling growth.

Increasing prevalence of life-threatening allergies and rising demand for these devices are expected to aid growth. As per the Food Allergy Research & Education, around 200, 000 people every year need emergency medical care for allergic food reactions.

In addition, increasing approvals are anticipated to drive growth. For instance, in August 2018, U.S. FDA approved the first generic epinephrine auto-injector of Teva Pharmaceuticals to treat emergency allergic reactions, including anaphylaxis. Generic versions of EpiPen Jr & EpiPen of 0.15 mg & 0.3 mg, respectively, are indicated for pediatric and adult patients weighing more than 33 pounds.

Moreover, manufacturers are also developing new products and innovative technologies, which is expected to propel market growth. For instance, in June 2018, AbbVie GK launched Humira, which is a fully human antitumor necrosis factor alpha monoclonal antibody formulation with lock function & injection start & end alerts as well as an inspection window and injects completely in 10 seconds. Demand for these devices is increasing as they are designed in accordance with patient acceptance and compliance. Technological advancements are anticipated to make them more convenient and user-friendly. This is encouraging patients to adopt this technology for chronic illnesses.

 Request a free sample copy or view report summary: Auto-injectors Market Report

Autoinjectors Market Report Highlights

• The disposable autoinjectors segment accounted for the largest market share of 56.8% in 2024 and is expected to witness the fastest CAGR over the forecast period. The reusable auto injector segment is witnessing significant growth, driven by increasing patient preference for convenience and cost-effectiveness.

• The diabetes segment accounted for the largest market share of 28.9% in 2024. The multiple sclerosis (MS) segment is expected to witness the fastest growth over the forecast period.

• The homecare settings segment accounted for the largest revenue share of 54.1% in 2024 and is expected to witness the fastest growth over the forecast period. The hospitals and clinics segment is also expected to witness significant growth over the forecast period.

• The North America autoinjectors market dominated the overall global market and accounted for the 45.3% revenue share in 2024. The autoinjectors market in the U.S. held a significant share of North America's auto-injectors industry in 2024.

Autoinjectors Market Segmentation

Grand View Research has segmented the global auto-injectors market report on the basis of product, indication, end-use and region:

Autoinjectors Product Outlook (Revenue, USD Million; 2018 - 2030)

• Disposable auto-injectors

• Reusable auto-injectors

  • Prefilled

  • Empty

Autoinjectors Indication Outlook (Revenue, USD Million; 2018 - 2030)

• Rheumatoid Arthritis

• Multiple Sclerosis

• Diabetes

• Anaphylaxis

• Other Therapies

Autoinjectors End-use Outlook (Revenue, USD Million; 2018 - 2030)

• Homecare Settings

• Hospitals & Clinics

• Ambulatory Surgical Centers

Autoinjectors Region Outlook (Revenue, USD Million; 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Autoinjectors Market

• Eli Lilly

• SHL Medical AG

• AbbVie, Inc.

• Amgen

• Owen Mumford

• Ypsomed

• Teva Pharmaceutical

• Biogen Idec

• Mylan N.V.

• Pfizer, Inc.

• Sanofi

• Gerresheimer